| Pair Name | Silibinin, Sorafenib | ||
| Phytochemical Name | Silibinin (PubChem CID: 31553 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Silibinin, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | KLF4 | hsa9314 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Down-regulation | Expression | MCL1 | hsa4170 | |
| Down-regulation | Expression | NANOG | hsa79923 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| In Vitro Model | BEL-7404 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6568 |
| Result | These results suggested that silibinin improved the efficacy of sorafenib in HCC therapy, indicating a clinical promising therapeutic strategy for HCC patients. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Eur J Pharmacol. 2018 Aug 5;832:39-49. doi: 10.1016/j.ejphar.2018.05.027. | Click |
